Royal Bank of Canada Sells 26,972 Shares of Omnicell, Inc. $OMCL

Royal Bank of Canada lowered its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 3.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 685,206 shares of the company's stock after selling 26,972 shares during the period. Royal Bank of Canada owned 1.46% of Omnicell worth $23,955,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OMCL. Lazard Asset Management LLC lifted its position in shares of Omnicell by 81.6% in the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after purchasing an additional 737,536 shares during the period. Toronto Dominion Bank acquired a new position in shares of Omnicell during the 4th quarter valued at $30,637,000. Pacer Advisors Inc. acquired a new position in shares of Omnicell during the 1st quarter valued at $10,542,000. Nuveen LLC acquired a new position in shares of Omnicell during the 1st quarter valued at $6,218,000. Finally, Wellington Management Group LLP lifted its position in shares of Omnicell by 52.6% during the 1st quarter. Wellington Management Group LLP now owns 496,680 shares of the company's stock valued at $17,364,000 after acquiring an additional 171,116 shares during the period. Institutional investors and hedge funds own 97.70% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on OMCL. Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company boosted their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Piper Sandler dropped their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Finally, Bank of America boosted their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Omnicell presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Stock Down 4.4%

OMCL traded down $1.45 during mid-day trading on Friday, reaching $31.83. 492,448 shares of the stock were exchanged, compared to its average volume of 500,188. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. The stock has a market capitalization of $1.46 billion, a PE ratio of 63.66, a price-to-earnings-growth ratio of 7.27 and a beta of 0.82. The company has a 50 day moving average price of $30.71 and a two-hundred day moving average price of $31.05. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.